Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQSTAA) and the best and worst performers in the medical devices & supplies - specialty industry.
Medical technology company Enovis Corporation (NYSEENOV) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 23.3% year on year to $561 million. On the other hand, the company’s full-year revenue guidance of $2.21 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $0.98 per share was 7% above analysts’ consensus estimates.
JMP Securities initiates coverage on Enovis Corporation with a Market Outperform rating, highlighting its strategic acquisitions, including LimaCorporate, and future growth potential. The analyst notes the company's undervaluation and sees revenue catalysts ahead.
The medical info systems industry is thriving due to the growing demand for contactless services. Amid this environment, here are some stocks in the industry that may see stable returns in 2024.
Enovis reports Q4 results with net sales surging 11% YoY, reaching $455 million. The growth is attributed to strong performance in P&R and above-market expansion in Recon, coupled with recent acquisitions impact.
William Bliar has initiated coverage on Enovis Corp (NYSEENOV), a medical technology company focusing on the orthopedics market valued at approximately $25 billion, experiencing steady growth, especially in sub-categories such as extremities, which are growing rapidly due to
Enovis Corporation (NYSEENOV) shares are trading lower on Thursday after the company announced a proposed private offering of $400 million of convertible senior notes and issued
